Cargando…
Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer
BACKGROUND: Polycomb repressive complex 2 (PRC2) mediates gene silencing through histone H3K27 methylation. PRC2 components are over-expressed in metastatic prostate cancer (PC), and are required for cancer stem cell (CSC) self-renewal. 3-Dezaneplanocin-A (DZNeP) is an inhibitor of PRC2 with broad a...
Autores principales: | Crea, Francesco, Hurt, Elaine M, Mathews, Lesley A, Cabarcas, Stephanie M, Sun, Lei, Marquez, Victor E, Danesi, Romano, Farrar, William L |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3100246/ https://www.ncbi.nlm.nih.gov/pubmed/21501485 http://dx.doi.org/10.1186/1476-4598-10-40 |
Ejemplares similares
-
Clinical significance of Polycomb gene expression in brain tumors
por: Crea, Francesco, et al.
Publicado: (2010) -
Epigenetic regulation of CpG promoter methylation in invasive prostate cancer cells
por: Mathews, Lesley A, et al.
Publicado: (2010) -
DNA repair: the culprit for tumor-initiating cell survival?
por: Mathews, Lesley A., et al.
Publicado: (2011) -
De Novo Polycomb Recruitment and Repressive Domain Formation
por: Hernández-Romero, Itzel Alejandra, et al.
Publicado: (2022) -
Molecular architecture of polycomb repressive complexes
por: Chittock, Emily C., et al.
Publicado: (2017)